Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years
Biogen has released the latest interim clinical trial data for its early-stage Alzheimer's disease candidate drug, diranersen.
According to information from Zhitong Finance APP, diranersen from Biogen (BIIB.US), used for early-stage Alzheimer's disease, showed in phase 2 open-label extension data that the investigational drug significantly slowed clinical decline over two years.
With a dosing regimen of 60 milligrams every six months, diranersen provided a 38% clinical benefit improvement at week 96 based on the Clinical Dementia Rating-Sum of Boxes (CDR-SB). This corresponds to a treatment difference of 1.09 points, a magnitude considered highly clinically significant by clinicians. The benefit increased over time—by week 76, the improvement was 26%.
Between week 76 and week 96, improvements in other measurement indicators were as follows: ADAS-Cog13 increased from 42% to 54%; ADCS-ADL-MCI from 0% to 30%; ADCOMS from 23% to 38%; and modified iADRS from 30% to 46%.
When the main results of the CELIA trial were announced in July, diranersen failed to meet its primary endpoint—the change in CDR-SB at week 76.
Diranersen is an antisense oligonucleotide therapy targeting tau protein. Tau is a structural protein in the brain that forms tangles in the brains of Alzheimer's disease patients.
Most other Alzheimer's disease therapies target beta-amyloid plaques in the brain. However, according to Stanford University School of Medicine, tau tangles are considered closely related to the actual degree of cognitive decline and the severity of symptoms.
Biogen obtained the global exclusive license for diranersen from Ionis Pharmaceuticals (IONS.US) in December 2019.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Report: Apple Plans to Establish Multi-Year DRAM Agreement with Samsung, Deliveries to Begin in First Half of 2027
Apple and Samsung are in negotiations for a long-term DRAM chip supply agreement lasting four to five years, with deliveries expected to start in the first half of 2027. The agreement is expected to include a minimum supply commitment and set pricing linked to the market. Currently, Apple is one of the few major tech companies that have yet to sign a long-term DRAM supply deal with Samsung.

Bitcoin's $90,000 Comeback Now Unlikely, Novogratz Warns

MMT rises over 50% again, currently trading at $0.2144

Anthropic’s IPO Pricing Is Today: Here’s What Investors Should Expect
